The European Medicines Agency (EMA) has recommended extending the use of Mounjaro to younger patients with diabetes, alongside a reduced-calorie diet and increased exercise.
The technique capitalizes on exponential moving averages (EMA). One possible trade might involve Rocket Lab December 55 puts, just above the 50-day EMA.
The EMA’s drug safety committee launched a review of medicines containing semaglutide — the active ingredient in Ozempic, Wegovy and Rybelsus — in January.